产品
编 号：F178571
分子式：C23H24FN3O3
分子量：409.45
分子式：C23H24FN3O3
分子量：409.45
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1514888-56-2
产品详情
生物活性：
Icanbelimod (S1p receptor agonist 1) is a potent and orally active S1P receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). Icanbelimod is extracted from patent WO2015039587A1, Compound 2.
体内研究：
Icanbelimod (oral administration; 0.01 mg/kg-1 mg/kg) at all dose is active, and only a dose of 0.01 mg/kg is required to observe a decrease in the number of peripheral blood lymphocytes by more than 50% and a decrease in the 1 mg/kg dose. Besides, this compound islymphocyte-specific, which dose not significantly alter the number of peripheral monocytes and other white blood cells in SD rats.Icanbelimod (oral administration; 3 mg/kg; 12 days)is has been proved to block lymphocyte efflux. In the development of type II collagen-induced arthritis in rat model, compound 2 is effective in inhibiting the development of joint swelling in arthritis andjoint structure destruction.Icanbelimod (oral administration; 0.3-1mg/kg; 30 days; once daily) inhibits the development of experimental autoimmune encephalitis (EAE) as a dose-dependent manner in mice model.Animal Model:Lewis rats
Dosage:3 mg/kg
Administration:Oral administration
Result:Decreased the severity score of arthritis in the four-legged rats.
Animal Model:Female C57BL/6 mice?
Dosage:0.03, 0.1, and 1 mg/kg
Administration:Oral administration
Result:Decreased the severity score of EAE in MOG 35-55?induced mice.
Icanbelimod (S1p receptor agonist 1) is a potent and orally active S1P receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). Icanbelimod is extracted from patent WO2015039587A1, Compound 2.
体内研究：
Icanbelimod (oral administration; 0.01 mg/kg-1 mg/kg) at all dose is active, and only a dose of 0.01 mg/kg is required to observe a decrease in the number of peripheral blood lymphocytes by more than 50% and a decrease in the 1 mg/kg dose. Besides, this compound islymphocyte-specific, which dose not significantly alter the number of peripheral monocytes and other white blood cells in SD rats.Icanbelimod (oral administration; 3 mg/kg; 12 days)is has been proved to block lymphocyte efflux. In the development of type II collagen-induced arthritis in rat model, compound 2 is effective in inhibiting the development of joint swelling in arthritis andjoint structure destruction.Icanbelimod (oral administration; 0.3-1mg/kg; 30 days; once daily) inhibits the development of experimental autoimmune encephalitis (EAE) as a dose-dependent manner in mice model.Animal Model:Lewis rats
Dosage:3 mg/kg
Administration:Oral administration
Result:Decreased the severity score of arthritis in the four-legged rats.
Animal Model:Female C57BL/6 mice?
Dosage:0.03, 0.1, and 1 mg/kg
Administration:Oral administration
Result:Decreased the severity score of EAE in MOG 35-55?induced mice.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备